Posts Archive

NCT03850522: Phase 2: PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma PD-L1 Peptide Vaccination in High Risk...

NCT03839459: Phase 2: Denosumab for Smoldering Multiple Myeloma Denosumab for Smoldering Multiple Myeloma This study will assess the...

Dara-KRd NCT04113018: Phase 2: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed...

NCT03942224: Phase 2: Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed...

NCT03820817: Phase 1: Rifaximin in Patients With Monoclonal Gammopathy MGUS Rifaximin in Patients With Monoclonal Gammopathy This trial...

LENAZART Study LEN-AZA-RT NCT04174196: Phase 2: A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma...

The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab,...

KarMMa-2 An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk...

PLEIADES study A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimen MMY2040...

NCT03757221: Phase 2 - Ixazomib -Daratumumab Without Dex (IDara) in Elderly RRMM (IDARA) IFM 2018-02 Phase 2 Study Elderly RRMM Ixazomib...

NCT03435796: Phase 2/3: Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells Long-Term Follow-up Protocol for...

IFM 2018-04 NCT03606577: Phase 2: An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell...

NCT03428373: Phase 2: Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma (RithMM) NCT03428373: Phase 2: Rivaroxaban or...

The purpose of this study is to evaluate the efficacy and safety of LCAR-B38M chimeric antigen receptor T (CAR-T) cells. CHINESE STUDY A...

HO147SMM NCT03673826: Phase 2: Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM...

A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous...

NCT03767257: Phase 2: A Study of Colesevelam for Lenalidomide-Associated Diarrhea NCT03767257: Phase 2: A Study of Colesevelam for...

NCT03756896: Phase 2: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma KPd Carfilzomib,...

NCT03544281: Phase 2: To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in...